Literature DB >> 34147748

Design, synthesis and biological evaluation of exiguamine A analogues as IDO1 inhibitors.

Junmin Dong1, Xuan Pan1, Ying Yang1, Guangyan Zhang1, Zhiyan Xiao1, Zhanzhu Liu2.   

Abstract

A series of exiguamine A analogues were designed and synthesized via 15 steps. Their inhibitory activities against IDO1 were tested and the structure-activity relationships were studied. Most compounds exhibited potent IDO1 inhibitory activities with IC50 values at the level of 10-7-10-8 M. Compound 21f was the most potent IDO1 inhibitor with an IC50 value of 65.3 nM, which was comparable with the positive control drug epacadostat (IC50 = 46 nM). Moreover, compound 21f showed higher selectivity for IDO1 over tryptophan 2,3-dioxygenase (TDO) and no cytotoxicity at its effective concentration, rending it justifiable for further optimization and evaluation.
Copyright © 2021 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Cancer immunotherapy; Exiguamine A; Indoleamine 2,3-dioxygenase 1

Year:  2021        PMID: 34147748     DOI: 10.1016/j.ejmech.2021.113631

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  1 in total

1.  Novel 1,2,3-Triazole Erlotinib Derivatives as Potent IDO1 Inhibitors: Design, Drug-Target Interactions Prediction, Synthesis, Biological Evaluation, Molecular Docking and ADME Properties Studies.

Authors:  Gui-Qing Xu; Xiao-Qing Gong; Ying-Ying Zhu; Xiao-Jun Yao; Li-Zeng Peng; Ge Sun; Jian-Xue Yang; Long-Fei Mao
Journal:  Front Pharmacol       Date:  2022-05-23       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.